Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, The University of Western Australia, Perth, Australia; Division of Paediatrics, School of Medicine, The University of Western Australia, Perth, Australia.
Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, The University of Western Australia, Perth, Australia.
Vaccine. 2021 Sep 7;39(38):5401-5409. doi: 10.1016/j.vaccine.2021.07.085. Epub 2021 Aug 9.
Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity. This study investigated PCV13 impact on serotype-specific pneumococcal carriage prevalence, density, and serotype diversity in PNG infants, who have some of the highest reported rates of pneumococcal carriage and disease in the world.
Nasopharyngeal swabs were collected at 1, 4 and 9 months of age from PCV13-vaccinated infants (n = 57) and age-/season-matched, unvaccinated infants (at approximately 1 month, n = 53; 4 months, n = 57; 9 months, n = 52). Serotype-specific pneumococcal carriage density and antimicrobial resistance genes were identified by qPCR and microarray.
Pneumococci were present in 89% of swabs, with 60 different serotypes and four non-encapsulated variants detected. Multiple serotype carriage was common (47% of swabs). Vaccine type carriage prevalence was similar between PCV13-vaccinated and unvaccinated infants at 4 and 9 months of age. The prevalence of non-vaccine type carriage was also similar between cohorts, with non-vaccine types present in three-quarters of samples (from both vaccinated and unvaccinated infants) by 4 months of age. The median pneumococcal carriage density was high and similar at each age group (~7.0 loggenome equivalents/mL). PCV13 had no effect on overall pneumococcal carriage density, vaccine type density, non-vaccine type density, or the prevalence of antimicrobial resistance genes.
PNG infants experience dense and diverse pneumococcal colonisation with concurrent serotypes from 1 month of age. PCV13 had no impact on pneumococcal carriage density, even for vaccine serotypes. The low prevalence of vaccine serotypes, high pneumococcal carriage density and abundance of non-vaccine serotypes likely contribute to the lack of PCV13 impact on carriage in PNG infants. Indirect effects of the infant PCV programs are likely to be limited in PNG. Alternative vaccines with broader coverage should be considered.
巴布亚新几内亚(PNG)于 2014 年引入了 13 价肺炎球菌结合疫苗(PCV13),并在 1、2 和 3 个月龄时进行接种。PCV13 降低或消除了低肺炎球菌携带率、携带密度和血清型多样性人群中的疫苗血清型携带。本研究调查了 PCV13 对 PNG 婴儿中血清型特异性肺炎球菌携带率、密度和血清型多样性的影响,这些婴儿的肺炎球菌携带和疾病报告率在世界上是最高的。
从接种了 PCV13 的婴儿(n=57)和年龄/季节匹配的未接种婴儿(约 1 个月龄时 n=53;4 个月龄时 n=57;9 个月龄时 n=52)的鼻咽拭子中收集标本。通过 qPCR 和微阵列鉴定血清型特异性肺炎球菌携带密度和抗菌药物耐药基因。
89%的拭子中存在肺炎球菌,共检测到 60 种不同血清型和 4 种非囊泡变体。多种血清型携带很常见(47%的拭子)。4 个月和 9 个月龄时,PCV13 疫苗接种组和未接种组的疫苗血清型携带率相似。两组的非疫苗血清型携带率也相似,4 个月龄时,75%的样本(来自接种和未接种婴儿)中都存在非疫苗血清型。肺炎球菌携带密度中位数较高,且在各年龄组相似(~7.0 loggenome 个/mL)。PCV13 对总体肺炎球菌携带密度、疫苗血清型密度、非疫苗血清型密度或抗菌药物耐药基因的流行率均无影响。
PNG 婴儿从 1 个月龄起就经历了密集且多样化的肺炎球菌定植,同时存在多种血清型。PCV13 对肺炎球菌携带密度没有影响,即使是疫苗血清型。疫苗血清型低流行率、高肺炎球菌携带密度和丰富的非疫苗血清型可能是导致 PCV13 对 PNG 婴儿携带无影响的原因。婴儿 PCV 计划的间接影响在 PNG 可能有限。应考虑使用具有更广泛覆盖范围的替代疫苗。